Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis

Journal of Immunology

Volumn 176, Issue 11, 2006, Pages 7119-7129

  Tennakoon, Deepani K ^a   Mehta, Riyaz S ^a   Ortega, Sterling B ^a   Bhoj, Vijay ^a   Racke, Michael K ^a,b   Karandikar, Nitin J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GLATIRAMER; HLA ANTIGEN CLASS 1; HLA E ANTIGEN;

ARTICLE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CELL CONTACT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VIVO STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

EID: 33646879037     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.11.7119     Document Type: Article

References (61)

1. Arnason, B. G. 1983. Relevance of experimental allergic encephalomyelitis to multiple sclerosis. Neurol. Clin. 1: 765-782.
2. Martin, R., H. F. McFarland, and D. E. McFarlin. 1992. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10: 153-187.
3. + T cells in a model for multiple sclerosis. J. Exp. Med. 194: 669-676.
4. + T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J. Immunol. 166: 7579-7587.
5. + T cells in multiple sclerosis. Autoimmunity 23: 127-138.
6. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192: 393-404.
7. + T-cell responses to human myelin protein-derived peptides. Proc. Natl. Acad. Sci. USA 91: 10859-10863.
8. + T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 103: 4222-4231.
9. + T cells is mediated by interferon-γ and is defective in chronic progressive multiple sclerosis. J. Clin. Invest. 95: 2711-2719.
10. + cell lines from patients with progressive multiple sclerosis. J. Immunol. 137: 3436-3439.
11. + memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin. Diagn. Lab. Immunol. 2: 249-252.
12. -/- mice. Science 256: 1210-1213.
13. + T cell responses in patients with multiple sclerosis. J. Clin. Invest. 109: 641-649.
14. - T cells in an autoimmune disease model. J. Clin. Invest. 112: 1037-1048.
15. Jiang, H., and L. Chess. 2004. An integrated model of immunoregulation mediated by regulatory T cell subsets. Adv. Immunol. 83: 253-288.
16. + suppressor T cells. Nat. Immunol. 5: 469-471.
17. Hu, D., K. Ikizawa, L. Lu, M. E. Sanchirico, M. L. Shinohara, and H. Cantor. 2004. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat. Immunol. 5: 516-523.
18. Jiang, H., Y. Wu, B. Liang, Z. Zheng, G. Tang, J. Kanellopoulos, M. Soloski, R. Winchester, I. Goldstein, and L. Chess. 2005. An affinity/avidity model of peripheral T cell regulation. J. Clin. Invest. 115: 302-312.
19. Teitelbaum, D., A. Meshorer, T. Hirshfeld, R. Arnon, and M. Sela. 1971. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1: 242-248.
20. Keith, A. B., R. Arnon, D. Teitelbaum, E. A. Caspary, and H. M. Wisniewski. 1979. The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J. Neurol. Sci. 42: 267-274.
21. Bornstein, M. B., A. I. Miller, D. Teitelbaum, R. Arnon, and M. Sela. 1982. Multiple sclerosis: trial of a synthetic polypeptide. Ann. Neurol. 11: 317-319.
22. Johnson, K. P., B. R. Brooks, C. C. Ford, A. Goodman, J. Guarnaccia, R. P. Lisak, L. W. Myers, H. S. Panitch, A. Pruitt, J. W. Rose, et al. 2000. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years: Copolymer 1 Multiple Sclerosis Study Group. Mult. Scler. 6: 255-266.
23. Johnson, K. P., B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein, R. P. Lisak, L. W. Myers, H. S. Panitch, J. W. Rose, and R. B. Schiffer. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis-results of a phase III multicenter, double-blind placebo-controlled trial: the Copolymer 1 Multiple Sclerosis Study Group. Neurology 45: 1268-1276.
24. Miller, A., S. Shapiro, R. Gershtein, A. Kinarty, H. Rawashdeh, S. Honigman, and N. Lahat. 1998. Treatment of multiple sclerosis with Copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol. 92: 113-121.
25. Brenner, T., R. Arnon, M. Sela, O. Abramsky, Z. Meiner, R. Riven-Kreitman, N. Tarcik, and D. Teitelbaum. 2001. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J. Neuroimmunol. 115: 152-160.
26. Duda, P. W., M. C. Schmied, S. L. Cook, J. I. Krieger, and D. A. Hafler. 2000. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 105: 967-976.
27. Farina, C., F. Then Bergh, H. Albrecht, E. Meinl, A. Yassouridis, O. Neuhaus, and R. Hohlfeld. 2001. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-γ response in blood cells. Brain 124: 705-719.
28. Aharoni, R., D. Teitelbaum, O. Leitner, A. Meshorer, M. Sela, and R. Arnon. 2000. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by Copolymer 1. Proc. Natl. Acad. Sci. USA 97: 11472-11477.
29. Gran, B., L. R. Tranquill, M. Chen, B. Bielekova, W. Zhou, S. Dhib-Jalbut, and R. Martin. 2000. Mechanisms of immunomodulation by glatiramer acetate. Neurology 55: 1704-1714.
30. Neuhaus, O., C. Farina, H. Wekerle, and R. Hohlfeld. 2001. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56: 702-708.
31. Dhib-Jalbut, S., M. Chen, A. Said, M. Zhan, K. P. Johnson, and R. Martin. 2003. Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J. Neuroimmunol. 140: 163-171.
32. Chen, M., B. Gran, K. Costello, K. Johnson, R. Martin, and S. Dhib-Jalbut. 2001. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult. Scler. 7: 209-219.
33. Chen, M., K. Conway, K. P. Johnson, R. Martin, and S. Dhib-Jalbut. 2002. Sustained immunological effects of glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J. Neurol. Sci. 201: 71-77.
34. Vieira, P. L., H. C. Heystek, J. Wormmeester, E. A. Wierenga, and M. L. Kapsenberg. 2003. Glatiramer acetate (copolymer-1, Copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J. Immunol. 170: 4483-4488.
35. Weber, M. S., M. Starck, S. Wagenpfeil, E. Meinl, R. Hohlfeld, and C. Farina. 2004. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 127: 1370-1378.
36. Kim, H. J., I. Ifergan, J. P. Antel, R. Seguin, M. Duddy, Y. Lapierre, F. Jalili, and A. Bar-Or. 2004. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J. Immunol. 172: 7144-7153.
37. + regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc. Natl. Acad. Sci. USA 102: 6449-6454.
38. Reddehase, M. J. 2002. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat. Rev. Immunol. 2: 831-844.
39. Sheehy, M., A. McDermott, S. Furlan, P. Klenerman, and D. Nixon. 2001. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J. Immunol. Methods 249: 99-110.
40. Liu, L., A. Chahroudi, G. Silvestri, M. E. Wernett, W. J. Kaiser, J. T. Safrit, A. Komoriya, J. D. Altman, B. Z. Packard, and M. B. Feinberg. 2002. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat. Med. 8: 185-189.
41. Lecoeur, H., M. Fevrier, S. Garcia, Y. Riviere, and M. Gougeon. 2001. A novel flow cytometric assay for quanti talion and multiparametric characterization of cell-mediated cytotoxicity. J. Immunol. Methods 253: 177-187.
42. Azuma, M., M. Cayabyab, J. H. Phillips, and L. L. Lanier. 1993. Requirements for CD28-dependent T cell-mediated cytotoxicity. J. Immunol. 150: 2091-2101.
43. Martinozzi, S., R. Pacasova, H. J. Boulouis, M. Ulbrecht, E. H. Weiss, F. Sigaux, and M. Pla. 1999. Cutting edge: requirement of class I signal sequence-derived peptides for HLA-E recognition by a mouse cytotoxic T cell clone. J. Immunol. 162: 5662-5665.
44. Borrego, F., M. Ulbrecht, E. H. Weiss, J. E. Coligan, and A. G. Brooks. 1998. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 187: 813-818.
45. + CTLs by TCR Vβ-derived peptides bound to HLA-E. J. Immunol. 167: 3800-3808.
46. Fridkis-Hareli, M., J. M. Neveu, R. A. Robinson, W. S. Lane, L. Gauthier, K. W. Wucherpfennig, M. Sela, and J. L. Strominger. 1999. Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J. Immunol. 162: 4697-4704.
47. Miller, J. D., D. A. Weber, C. Ibegbu, J. Pohl, J. D. Altman, and P. E. Jensen. 2003. Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2. J. Immunol. 171: 1369-1375.
48. Shevach, E. M. 2000. Regulatory T cells in autoimmunity. Annu. Rev. Immunol. 18: 423-449.
49. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199: 971-979.
50. Sercarz, E., E. Maverakis, P. van den Elzen, L. Madakamutil, and V. Kumar. 2003. Seven surprises in the TCR-centred regulation of immune responsiveness in an autoimmune system. Novartis Found Symp. 252: 165-171.
51. + T cells. Proc. Natl. Acad. Sci. USA 95: 4533-4537.
52. Zhang, J., R. Medaer, P. Stinissen, D. Hafler, and J. Raus. 1993. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 261: 1451-1454.
53. Madakamutil, L. T., I. Maricic, E. Sercarz, and V. Kumar. 2003. Regulatory T cells control autoimmunity in vivo by inducing apoptotic depletion of activated pathogenic lymphocytes. J. Immunol. 170: 2985-2992.
54. Lehner, P. J., and P. Cresswell. 2004. Recent developments in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 16: 82-89.
55. Ackerman, A. L., C. Kyritsis, R. Tampe, and P. Cresswell. 2005. Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat. Immunol. 6: 107-113.
56. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8: 379-385.
57. + T cells. Blood 101: 2711-2720.
58. + regulatory T cells. Nat. Immunol. 4: 330-336.
59. + T regulatory cells. Nat. Immunol. 4: 337-342.
60. - T cells. J. Clin. Invest. 112: 1437-1443.
61. + T cells with a regulatory phenotype and function. Eur. J. Immunol. 35: 2896-2908.